NAMS
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$25.40
−1.74%Margins
Gross margin
92.1%
EBITDA margin
-3579.2%
EBIT margin
-3432.2%
Net margin
-3644.2%
FCF margin
-2018.3%
-41.1%
Return on equity
-36.8%
Return on assets
-38.7%
Return on invested capital
0.01x
Asset turnover
-$143.5M
Cash from operations
$5.30
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026